<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690195</url>
  </required_header>
  <id_info>
    <org_study_id>M11-428</org_study_id>
    <secondary_id>2012-000537-39</secondary_id>
    <nct_id>NCT01690195</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long term extension study to evaluate safety and tolerability of subjects who
      complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate
      Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term
      safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study
      M11-793. Up to 420 subjects may participate at approximately 40 sites in seven countries.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Data</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Assessments include hematology, clinical chemistry, urinalysis and urine drug/alcohol screens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Assessments include pulse, blood pressure and oral body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>An examination of bodily functions and physical condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Neurological examination</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Assessments include cranial nerves, motor and sensory system, reflexes, coordination, gait and station</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Psychiatric assessments</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Assessments include mood, anxiety, psychosis or delusions, agitation, homicidal thoughts or behaviors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>The scale is designed to assess suicidal behavior and ideation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cornell Scale for Depression in Dementia</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Assesses the signs and symptoms of major depression in patients with dementia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Assessments up through 28 weeks</time_frame>
    <description>Measurements include heart rate, RR interval, PR interval, QRS duration and QT intervals</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">343</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ABT-126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-126 Open-label dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-126</intervention_name>
    <description>See arm description</description>
    <arm_group_label>ABT-126</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject and caregiver must voluntarily sign and date an informed consent. If the
             subject does not have the capacity to provide informed consent, full informed consent
             must be obtained from the subject's representative and assent must be obtained from
             the subject.

          -  The subject was randomized into Study M11-793 and completed dosing through Week 24 in
             that study.

          -  With the exception of a diagnosis of mild to moderate AD and the presence of stable
             medical conditions, the subject is in general good health, based upon the results of
             medical history, physical examination, vital signs, laboratory profile, and a 12-lead
             ECG.

          -  If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is
             using a barrier method of birth control (condom) with spermicidal
             foam/gel/film/cream/suppository for the duration of the study and for 30 days
             following the last dose of study drug. However, if the male subject's partner has been
             postmenopausal for at least two years or is surgically sterile, then use of a barrier
             method of birth control is not required.

          -  The subject has an identified, reliable caregiver who will provide support and ensure
             compliance with the study medication and procedures, and provide accurate information
             about the subject's status during the study.

          -  The subject and caregiver must have sufficient visual, hearing and graphomotor skills
             to complete the study procedures.

        Exclusion Criteria:

          -  The subject experienced an adverse event or abnormal finding in physical examination,
             vital signs, laboratory profile and/or ECG measurements in Study M11-793 that
             indicates the subject could become medically unstable during the current study.

          -  The subject is currently taking or is expected to be prescribed any excluded
             medications without the approval of Abbott medical monitor.

          -  The subject was noncompliant with donepezil or rivastigmine during Study M11-793 or is
             expected to discontinue these medications prior to conclusion of this study.

          -  The subject anticipates a move outside the geographic area of the investigative site
             or is planning extended travel inconsistent with the recommended visit intervals.

          -  The subject is currently enrolled in, or plans to participate in, another experimental
             study during the course of this trial.

          -  The subject developed any significant medical or psychiatric condition that, in the
             opinion of the investigator, renders the subject an unsuitable candidate to
             participate in this study.

          -  For any other reason the investigator considers the subject to be an unsuitable
             candidate to receive ABT-126 or to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Gault, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84185</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84183</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109-4841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84187</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84178</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84180</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84186</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84182</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84181</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84179</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84173</name>
      <address>
        <city>Gatineau</city>
        <zip>J9A 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84174</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84177</name>
      <address>
        <city>Peterborough</city>
        <zip>K9H 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84175</name>
      <address>
        <city>Toronto</city>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84176</name>
      <address>
        <city>Verdun</city>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84376</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84373</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84374</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84377</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84375</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84382</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84380</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84383</name>
      <address>
        <city>Huettenberg</city>
        <zip>35625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84379</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84381</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84378</name>
      <address>
        <city>Schwerin</city>
        <zip>19053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84385</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84388</name>
      <address>
        <city>Athens</city>
        <zip>151 25</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84389</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84386</name>
      <address>
        <city>Haidari, Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84390</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84395</name>
      <address>
        <city>Belville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84391</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84393</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84394</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84392</name>
      <address>
        <city>Rosebank</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84398</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84397</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84400</name>
      <address>
        <city>London</city>
        <zip>TW8 8DS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84399</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

